Sociodemographic impact on survival in unresectable hepatocellular carcinoma: a survival epidemiology and end results study

被引：9

作者：

Kokabi, Nima ^{[1
]}

Xing, Minzhi ^{[2
]}

Duszak, Richard, Jr. ^{[1
]}

Howard, David H. ^{[3
]}

Applegate, Kimberly E. ^{[1
]}

Camacho, Juan C. ^{[1
]}

Kim, Hyun S. ^{[2
,4
]}

机构：

[1] Emory Univ, Sch Med, Dept Radiol & Imaging Sci, Atlanta, GA 30322 USA

[2] Yale Univ, Sch Med, Div Intervent Radiol, Dept Diagnost Radiol, New Haven, CT 06519 USA

[3] Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, Atlanta, GA 30322 USA

[4] Yale Univ, Yale Canc Ctr, New Haven, CT 06520 USA

来源：

FUTURE ONCOLOGY | 2016年 / 12卷 / 02期

关键词：

access to care; cancer-directed therapy; demographic; disparity; HCC; SEER; socioeconomic; survival; unresectable; UNITED-STATES; RISING INCIDENCE; LIVER-CANCER; CHEMOEMBOLIZATION; RADIOEMBOLIZATION; OUTCOMES; THERAPY; UNDERUTILIZATION; METAANALYSIS; STRATEGY;

D O I：

10.2217/fon.15.242

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To investigate outcomes in unresectable hepatocellular carcinoma (HCC) patients stratified by sociodemographic and clinical factors in a population study. Materials & methods: Surveillance, Epidemiology and End Results (SEER) database was used to identify patients diagnosed in 2000-2011. Overall survival (OS) was stratified using patient sociodemographic characteristics and American Joint Commission on Cancer (AJCC) staging. Log-rank test and Cox proportional hazard models were used to identify prognostic factors of OS. Results: In patients with AJCC stage I and II unresectable HCC, prolonged OS was correlated with being married, younger age, ethnicity, geographic location, living in large urban areas, being insured and higher income and education levels. Conclusion: In AJCC stage I and II unresectable HCC patients with favorable sociodemographic factors, prolonged OS maybe in part related to better access to cancer-directed therapy.

引用

页码：183 / 198

页数：16

共 44 条

[1] Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005
Altekruse, Sean F.
McGlynn, Katherine A.
Reichman, Marsha E.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) : 1485 - 1491
[2] [Anonymous], CA CANC J CLIN
[3] Primary liver cancer:: Worldwide incidence and trends
Bosch, FX
Ribes, J
Díaz, M
Cléries, R
[J]. GASTROENTEROLOGY, 2004, 127 (05) : S5 - S16
[4] Management of Hepatocellular Carcinoma: An Update
Bruix, Jordi
Sherman, Morris
[J]. HEPATOLOGY, 2011, 53 (03) : 1020 - 1022
[5] Utilization and Outcomes of Palliative Therapy for Hepatocellular Carcinoma A Population-based Study in the United States
Davila, Jessica A.
Duan, Zhigang
McGlynn, Katherine A.
El-Serag, Hashem B.
[J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2012, 46 (01) : 71 - 77
[6] Interventional Radiological Treatment of Hepatocellular Carcinoma
Davis, Cliff R.
[J]. CANCER CONTROL, 2010, 17 (02) : 87 - 99
[7] Comparison of Conventional Transarterial Chemoembolization (TACE) and Chemoembolization With Doxorubicin Drug Eluting Beads (DEB) for Unresectable Hepatocelluar Carcinoma (HCC)
Dhanasekaran, Renumathy
Kooby, David A.
Staley, Charles A.
Kauh, John S.
Khanna, Vinit
Kim, Hyun S.
[J]. JOURNAL OF SURGICAL ONCOLOGY, 2010, 101 (06) : 476 - 480
[8] The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update
El-Serag, H
Davila, JA
Petersen, NJ
McGlynn, KA
[J]. ANNALS OF INTERNAL MEDICINE, 2003, 139 (10) : 817 - 823
[9] Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis
El-Serag, Hashem B.
Rudolph, Lenhard
[J]. GASTROENTEROLOGY, 2007, 132 (07) : 2557 - 2576
[10] Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: A population-based study
El-Serag, HB
Siegel, AB
Davila, JA
Shaib, YH
Cayton-Woody, M
McBride, R
McGlynn, KA
[J]. JOURNAL OF HEPATOLOGY, 2006, 44 (01) : 158 - 166

← 1 2 3 4 5 →